Dr. Bekim Sadikovic, section head for the molecular genetics laboratories, and Dr. Mark Vincent, oncologist, in the lab where EGFR mutations are tested using the circulating tumour DNA in a patient’s blood.

From left: Dr. Bekim Sadikovic, section head for the molecular genetics laboratories, and Dr. Mark Vincent, oncologist, in the lab where EGFR mutations are tested using the circulating tumour DNA in a patient’s blood.

A first of its kind laboratory test in Canada provides patients with non-small cell lung cancer a non-invasive option to be tested for a gene mutation and receive life-extending second line therapy medication

London Health Sciences Centre - 

A first of its kind laboratory test in Canada validated at London Health Sciences Centre (LHSC) and made possible by research at Lawson Health Research Institute provides patients with non-small cell lung cancer a non-invasive option to be tested for a gene mutation and receive life-extending second line therapy medication.

Non-small cell lung cancers account for nearly 85 per cent of all lung cancers, with 10 cent of those tumors experiencing a mutation in the epidermal growth factor receptor (EGFR) gene.

Jan Richardson, Dr. Cheryl Forchuk, Gordon Russell, and Peter Rozeluk

From left: Jan Richardson, manager, Homelessness Prevention, City of London; Dr. Cheryl Forchuk, assistant scientific director at Lawson, and professor of Nursing at Western University; Gordon Russell, director of shelters at Mission Services of London; and Peter Rozeluk, executive director at Mission Services of London gather to share the results of the Prevention of Homelessness Among Families (PHAF) project

Prevention of Homelessness Among Families (PHAF) project assesses the effectiveness of a shelter diversion pilot-program at Rotholme Women’s and Family Shelter (Mission Services)

St. Joseph’s: Parkwood Institute - 

Lawson Health Research Institute, Western UniversityCity of London, and Mission Services of London, Ontario, partnered on the Prevention of Homelessness Among Families (PHAF) project to assess the effectiveness of a shelter diversion pilot-program at Rotholme Women’s and Family Shelter (Mission Services).

Drs. David Palma and Alexander Louie

Drs. David Palma (left) and Alexander Louie (right), scientists at Lawson Health Research Institute and radiation oncologists at the London Regional Cancer Program at London Health Sciences Centre (LHSC).

Study aims to reduce the effects of radiation on esophagus and swallowing

LHSC: London Regional Cancer Program - 

While palliative radiation therapy is used to ease pain in patients with advanced lung cancer, it often has adverse effects on the esophagus which leads to symptoms like heartburn and difficulty swallowing. Through the PROACTIVE clinical trial, Lawson Health Research Institute scientist Dr. Alexander Louie is testing new palliative radiation techniques to spare these effects on the esophagus and improve quality of life for lung cancer patients.

Pages